Schaeffer's Top Stock Picks for '25

The Drug Stock Down 60% After FDA Rejection

ACRX stock has gone from an annual high Wednesday to within pennies of an annual low

Managing Editor
Oct 12, 2017 at 10:05 AM
facebook X logo linkedin


U.S. stocks are trading slightly lower this morning, as third-quarter earnings season commences. Among the stocks making moves this morning are banking institution and blue-chip powerhouse JPMorgan Chase & Co (NYSE:JPM), pizza restaurant chain Domino's Pizza, Inc. (NYSE:DPZ), and drugmaker AcelRx Pharmaceuticals Inc (NASDAQ:ACRX). Here's a closer look at what's moving shares of JPM, DPZ, and ACRX.

JPMorgan Stock Dips After Earnings

While JPMorgan Chase reported better-than-expected third-quarter earnings, the bank's bond trading revenue was weaker than forecast. The blue-chip stock was last seen trading fractionally lower at $96.67, likely to the dismay of recent options traders. JPM's Schaeffer's put/call open interest ratio (SOIR) of 0.66 ranks in only the 7th percentile of its annual range, which suggests that near-term options traders have rarely been more call biased in the past 12 months. Still, JPM stock has added more than 12% in 2017, and touched a record high of $97.64 on Oct. 6.

DPZ Stock Takes a Breather After Same-Store Sales Miss

Shares of Domino's Pizza have dipped 2.4% to $204.20, but seem to have found support at their 10-day and 20-day moving averages. While the pizza company reported better-than-expected third-quarter earnings, same-store sales growth fell short of expectations. Prior to today, Domino's stock had been on a tear, rallying roughly 20% from its August lows amid a sea of skepticism. Just five of 15 analysts consider DPZ stock worthy of a "buy" or better rating, leaving the door wide open for upgrades if the equity resumes its recent ascent.

ACRX Stock Flatlines After FDA Rejection

ACRX shares have taken a major hit after the Food and Drug Administration (FDA) rejected the firm's opioid painkiller, Dsuvia. Just one day after touching an annual high of $5.75, the drug stock was last seen 60% lower at $2.15 -- within pennies of a new low. Some recent option buyers are likely cheering the news. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), ACRX sports a 50-day put/call volume ratio of 0.43, ranking in the 94th percentile of its annual range, suggesting options traders have bought to open puts over calls at a faster-than-usual clip during the past 10 weeks.
 
 

You have the chance to join one of Bernie's most exclusive programs, complete access at HUGE savings!

As we prepare for a new administration to take the reins in Washington, the near-term market landscape is rife with uncertainty.

The Federal Reserve has already hinted at the turbulence ahead, lowering its interest rate outlook for 2025.

Meanwhile, breakthroughs in artificial intelligence (AI), quantum computing, and other transformative sectors have unlocked incredible profit potential.

But these opportunities are fleeting, and timing is everything. That's where Quick-Hit Trader comes in.

Quick-Hit Trader is designed for precision and speed, getting you in and out of the market in a flash. While other investors scramble to navigate volatile conditions, you'll have access to expertly curated trades that leverage these rapid shifts to deliver explosive profits in short order.

This is your chance to capitalize on the fast-moving market like never before. Are you ready to make your move?